Companies /Healthcare
Boston Scientific Corp
NYSE: BSX Medical Devices
$44.19
▲ $2.21 (+5.26%) today
Markets open · 4:11pm ET

Boston Scientific (BSX) Q3 2026 Earnings

Reported Oct 28, 2026, 6:34am ET · SEC source
$0.73
Beat +0.94%
EPS · est. $0.72 Adjusted

Adjusted EPS of $0.73 excludes $0.14/share amortization expense, $0.02/share goodwill and intangible asset impairment charges, $0.04/share acquisition/divestiture-related net charges, $0.05/share restructuring and restructuring-related net charges, $0.04/share litigation-related net charges, $0.05/share deferred tax expenses, and other items

$5.1B
Beat +1.66%
Revenue · est. $5.1B
7 quarters
Consecutive EPS beats

How Did BSX Stock React to Q3 2026 Earnings?

% change · around the report
−5%0+5%Oct 28Oct 29report 6:34am ETearnings−0.2%−2.5%
−5%0+5%Oct 28Oct 29earnings−0.2%−2.5%
BSX −2.5%S&P 500 −0.2%
−5%0+5%Oct 28Oct 29report 6:34am ETearnings−1.3%−2.5%
−5%0+5%Oct 28Oct 29earnings−1.3%−2.5%
BSX −2.5%NASDAQ −1.3%
−8%−4%0+4%Oct 27Nov 2report 6:34am ETearnings−2.3%+1.4%
−8%−4%0+4%Oct 27Nov 2earnings−2.3%+1.4%
BSX +1.4%S&P 500 −2.3%
−8%−4%0+4%Oct 27Nov 2report 6:34am ETearnings−5.7%+1.4%
−8%−4%0+4%Oct 27Nov 2earnings−5.7%+1.4%
BSX +1.4%NASDAQ −5.7%
−5.84%
Day of report
+0.61%
Next session

Did BSX Beat Earnings? Q3 2026 Results

Yes. Boston Scientific reported Q3 2026 earnings of $0.73 a share on Oct 28, 2026, beating the $0.72 consensus estimate by 0.9%. Revenue was $5.1B against a $5.1B estimate.

Boston Scientific posted a resilient but clearly pressured third quarter, beating Wall Street expectations on both top and bottom lines even as a cybersecurity incident disclosed in August 2026 visibly weighed on results. Adjusted EPS of $0.73 edged past the $0.72 consensus by 0.94%, extending the company's streak of consensus beats to six consecutive quarters, while revenue of $5.14 billion topped estimates by 1.66%, though it grew just 1.4% year over year, a sharp deceleration from prior periods. The cybersecurity disruption was the dominant story, constraining operational momentum across most segments; Urology fell 3.2% and Endoscopy slipped 0.8%, while Neuromodulation provided a bright spot at 13.1% reported growth. GAAP EPS dropped to $0.40 from $0.51 a year ago, reflecting $81 million in litigation charges and $63 million in restructuring costs. Looking ahead, management issued a cautious outlook, guiding full-year 2026 organic growth to approximately 3.75% and adjusted EPS of $3.16 to $3.18, with Q4 net sales expected to decline between 3.0% and 1.0% as cyber-related headwinds persist.

Key Takeaways
  • Neuromodulation segment grew 13.1% reported and 13.0% organic, the strongest performing business unit
  • Cardiovascular segment grew 1.9% reported and organic
  • Latin America and Canada region grew 16.0% reported and 10.5% operational
  • EMEA grew 6.1% on an operational basis
  • August 2026 cybersecurity incident significantly impacted operations and slowed overall growth

“This has been a challenging year for Boston Scientific and I'm proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients.”

Boston Scientific CEO, on the earnings call

What Is Boston Scientific's Outlook?

For full year 2026, Boston Scientific estimates net sales growth of approximately 4.25% on a reported basis and approximately 3.75% on an organic basis, with adjusted EPS of $3.16 to $3.18. For Q4 2026, the company expects net sales to decline approximately (3.0)% to (1.0)% on both a reported and organic basis, with adjusted EPS of $0.77 to $0.79. The weak Q4 outlook reflects continued impacts from the August 2026 cybersecurity incident on operations and financial results.

BSX YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$2.0B$4.0B$5.1B$5.1BRevenue$3.5B$3.4BGross Profit$1.0B$828.0MOperating Income$755.0M$582.0MNet Income
$0$2.0B$4.0BRevenueGross ProfitOperating IncomeNet Income
BSX income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $5.1B $5.1B +1.4%
Gross Profit $3.4B $3.5B −3.2%
Operating Income $828.0M $1.0B −21.1%
Net Income $582.0M $755.0M −22.9%

BSX Revenue by Segment

Cardiovascular$3.4B+1.9%
Cardiology
MedSurg$1.7B+0.6%
Endoscopy$741.0M−0.8%
Urology$661.0M−3.2%
Peripheral Interventions
Neuromodulation$331.0M+13.1%

BSX Revenue by Geography

United States$3.3B+0.5%
EMEA$829.0M+4.4%
Asia Pacific$797.0M−0.6%
Latin America$203.0M+16.0%

Figures from SEC filings and company reports. Not investment advice.